Arcturus Therapeutics (ARCT) Projected to Post Earnings on Tuesday

Arcturus Therapeutics (NASDAQ:ARCT) will likely be releasing its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect Arcturus Therapeutics to post earnings of ($0.92) per share and revenue of $14.3180 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Arcturus Therapeutics Price Performance

Shares of NASDAQ:ARCT opened at $7.67 on Tuesday. The firm has a 50 day moving average of $7.07 and a 200 day moving average of $11.71. The company has a market capitalization of $217.90 million, a price-to-earnings ratio of -3.12 and a beta of 2.39. Arcturus Therapeutics has a 52 week low of $5.85 and a 52 week high of $24.17.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Wall Street Zen cut Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Roth Mkm initiated coverage on shares of Arcturus Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $20.00 price target for the company. Citigroup lowered their price target on shares of Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday, January 6th. HC Wainwright reduced their price objective on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Finally, Piper Sandler decreased their target price on shares of Arcturus Therapeutics from $140.00 to $72.00 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Institutional Investors Weigh In On Arcturus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ARCT. ARK Investment Management LLC increased its position in shares of Arcturus Therapeutics by 39.4% in the 4th quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock valued at $16,006,000 after acquiring an additional 738,378 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in shares of Arcturus Therapeutics by 1,371.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company’s stock valued at $10,177,000 after purchasing an additional 514,652 shares during the period. Millennium Management LLC acquired a new position in shares of Arcturus Therapeutics in the first quarter valued at about $4,892,000. Bank of America Corp DE raised its stake in shares of Arcturus Therapeutics by 112.0% in the third quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock worth $11,428,000 after purchasing an additional 327,626 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Arcturus Therapeutics by 170.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 391,227 shares of the biotechnology company’s stock worth $2,398,000 after purchasing an additional 246,499 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.